236 related articles for article (PubMed ID: 19954744)
61. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.
Fang S; Krahe R; Lozano G; Han Y; Chen W; Post SM; Zhang B; Wilson CD; Bachinski LL; Strong LC; Amos CI
PLoS One; 2010 May; 5(5):e10813. PubMed ID: 20520810
[TBL] [Abstract][Full Text] [Related]
62. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.
Leu JD; Wang CY; Tsai HY; Lin IF; Chen RC; Lee YJ
Oncol Rep; 2011 Jun; 25(6):1755-63. PubMed ID: 21479369
[TBL] [Abstract][Full Text] [Related]
63. The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme.
Khatri RG; Navaratne K; Weil RJ
J Neurosurg; 2008 Nov; 109(5):842-8. PubMed ID: 18976073
[TBL] [Abstract][Full Text] [Related]
64. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
[TBL] [Abstract][Full Text] [Related]
65. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients.
Phang BH; Linn YC; Li H; Sabapathy K
Eur J Cancer; 2008 Mar; 44(5):760-6. PubMed ID: 18313915
[TBL] [Abstract][Full Text] [Related]
66. Relationship between MDM2 and p53 alterations in colorectal cancer and their involvement and prognostic value in the Tunisian population.
Chaar I; Amara S; Khiari M; Ounissi D; Dhraif M; Ben Hamida AE; Gharbi L; Mzabi S; Bouraoui S
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):228-36. PubMed ID: 22914606
[TBL] [Abstract][Full Text] [Related]
67. Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk.
Samuel N; Id Said B; Guha T; Novokmet A; Li W; Silwal-Pandit L; Børrsen-Dale AL; Langerød A; Hudson TJ; Malkin D
Hum Mutat; 2017 Mar; 38(3):265-268. PubMed ID: 27957778
[TBL] [Abstract][Full Text] [Related]
68. Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G gene variants act on colorectal cancer development or progression?
Tuna G; Küçükhüseyin O; Arıkan S; Kaytan Sağlam E; Güler E; Cacına C; Oztop O; Turan S; Korkmaz G; Yaylım I
DNA Cell Biol; 2013 Jul; 32(7):400-8. PubMed ID: 23777425
[TBL] [Abstract][Full Text] [Related]
69. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area.
Huang CY; Su CT; Chu JS; Huang SP; Pu YS; Yang HY; Chung CJ; Wu CC; Hsueh YM
Toxicol Appl Pharmacol; 2011 Dec; 257(3):349-55. PubMed ID: 21982800
[TBL] [Abstract][Full Text] [Related]
70. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis.
Marcel V; Palmero EI; Falagan-Lotsch P; Martel-Planche G; Ashton-Prolla P; Olivier M; Brentani RR; Hainaut P; Achatz MI
J Med Genet; 2009 Nov; 46(11):766-72. PubMed ID: 19542078
[TBL] [Abstract][Full Text] [Related]
71. Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore.
Koh WP; Van Den Berg D; Jin A; Wang R; Yuan JM; Yu MC
Breast Cancer Res Treat; 2011 Dec; 130(3):1011-9. PubMed ID: 21833626
[TBL] [Abstract][Full Text] [Related]
72. The p53-HDM2 gene-gene polymorphism interaction is associated with the development of missed abortion.
Fang Y; Kong B; Yang Q; Ma D; Qu X
Hum Reprod; 2011 May; 26(5):1252-8. PubMed ID: 21339197
[TBL] [Abstract][Full Text] [Related]
73. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival.
Bartel F; Jung J; Böhnke A; Gradhand E; Zeng K; Thomssen C; Hauptmann S
Clin Cancer Res; 2008 Jan; 14(1):89-96. PubMed ID: 18172257
[TBL] [Abstract][Full Text] [Related]
74. Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk.
Liu G; Wheatley-Price P; Zhou W; Park S; Heist RS; Asomaning K; Wain JC; Lynch TJ; Su L; Christiani DC
Int J Cancer; 2008 Feb; 122(4):915-8. PubMed ID: 17957785
[TBL] [Abstract][Full Text] [Related]
75. MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk.
Krekac D; Brozkova K; Knoflickova D; Hrstka R; Muller P; Nenutil R; Vojtesek B
Oncology; 2008; 74(1-2):84-7. PubMed ID: 18547962
[TBL] [Abstract][Full Text] [Related]
76. MDM2 SNP309 accelerates colorectal tumour formation in women.
Bond GL; Menin C; Bertorelle R; Alhopuro P; Aaltonen LA; Levine AJ
J Med Genet; 2006 Dec; 43(12):950-2. PubMed ID: 16825430
[TBL] [Abstract][Full Text] [Related]
77. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
[TBL] [Abstract][Full Text] [Related]
78. The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.
Alhopuro P; Ylisaukko-Oja SK; Koskinen WJ; Bono P; Arola J; Järvinen HJ; Mecklin JP; Atula T; Kontio R; Mäkitie AA; Suominen S; Leivo I; Vahteristo P; Aaltonen LM; Aaltonen LA
J Med Genet; 2005 Sep; 42(9):694-8. PubMed ID: 16141004
[TBL] [Abstract][Full Text] [Related]
79. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
80. Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer.
Khan SA; Idrees K; Forslund A; Zeng Z; Rosenberg S; Pincas H; Barany F; Offit K; Laquaglia MP; Paty PB
J Surg Oncol; 2008 Jun; 97(7):621-5. PubMed ID: 18381604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
